The purpose of this study is to assess the antibody response to COVID-19 vaccination in a cohort of patients with sickle cell disease (SCD) and to assess vaccine and SCD related complications around the time of vaccination.
| Nicole Mortier | |
| 202-292-6005 | |
| [email protected] |
Years
HbSS, HbSC, HbSB0 thalassemia
Observational
All
Biological
Diagnosis of sickle cell disease (HbSS, HbSC, HbSB0 thalassemia, HbSB+ thalassemia, HbS/Other)
Has not received any COVID-19 vaccination prior to enrollment
Scheduled for a COVID-19 vaccination (type does not matter) as part of routine clinical care
Willing and able to sign consent
Unwilling to have labs drawn or complete study requirements.
Previous therapy curative of SCD (including bone marrow transplant and gene therapy)
Previous receipt of anti-COVID-19 antibody therapy